Literature DB >> 11319624

The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.

A S Majumdar1, D E Hughes, S P Lichtsteiner, Z Wang, J S Lebkowski, A P Vasserot.   

Abstract

In human cells, telomerase activity is regulated by transcriptional control of the telomerase reverse transcriptase gene (hTERT) whose product is the catalytic subunit of the enzyme. The hTERT promoter is active in virtually all types of tumors and immortal cells, but is silent in most adult somatic tissues. In this study, we placed the herpes simplex virus thymidine kinase gene under the control of the hTERT promoter with the aim of restricting its expression to tumor cells. In transfection experiments, the hTERT promoter driven thymidine kinase gene (hTERTp/TK) conferred ganciclovir sensitivity to all tumor and immortal cell lines tested, whereas normal somatic cells remained largely unaffected. Human hTERTp/TK-positive cancer cells implanted in nude mice developed into tumors that could be eradicated by ganciclovir treatment. The hTERTp/TK cassette was inserted into an adenovirus vector and its efficacy in reducing tumor growth was compared with that of an adenovirus carrying the thymidine kinase gene under the control of the cytomegalovirus immediate-early promoter (CMVp/TK). In a xenograft model using the human 143B osteosarcoma cell line, a single injection of either virus resulted in equivalent tumor regression and survival upon ganciclovir treatment. In animals injected intratumorally with the CMVp/TK adenovirus, expression of the thymidine kinase gene was detected in tumors, as well as in liver samples. Expression of the suicide gene in combination with ganciclovir resulted in severe liver histopathology and in an elevation of hepatic enzymes. In sharp contrast, when the hTERT promoter controlled the thymidine kinase gene, transgene expression was observed in tumors, but not in liver samples. Normal liver function in these animals was confirmed by serum levels of hepatic enzymes that were indistinguishable from those of control healthy mice. These results indicate that by restricting thymidine kinase expression to tumor cells, the hTERT promoter allows the tumoricidal effect of the suicidal gene to be exerted without detrimental consequences on healthy tissues and vital organs. The tight specificity of expression imparted by the hTERT promoter will assist the development of novel approaches to the treatment of a broad array of cancer types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319624     DOI: 10.1038/sj.gt.3301421

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

2.  Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy.

Authors:  Toshio Yawata; Yusuke Maeda; Makiko Okiku; Eri Ishida; Kazuhiro Ikenaka; Keiji Shimizu
Journal:  J Neurooncol       Date:  2011-02-24       Impact factor: 4.130

3.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

Review 4.  Is telomerase a viable target in cancer?

Authors:  C M Buseman; W E Wright; J W Shay
Journal:  Mutat Res       Date:  2011-07-23       Impact factor: 2.433

Review 5.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

6.  Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.

Authors:  Yuanqing Wu; Bingliang Fang; Xiulan Q Yang; Li Wang; Dongning Chen; Victor Krasnykh; Bing Z Carter; Jeffrey S Morris; Imad Shureiqi
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

Review 7.  Human telomerase and its regulation.

Authors:  Yu-Sheng Cong; Woodring E Wright; Jerry W Shay
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

8.  Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.

Authors:  Ting Liu; Hai-Jun Wu; Yu Liang; Xu-Jun Liang; Hui-Chao Huang; Yan-Zhong Zhao; Qing-Chuan Liao; Ya-Qi Chen; Ai-Min Leng; Wei-Jian Yuan; Gui-Ying Zhang; Jie Peng; Yong-Heng Chen
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

9.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

10.  Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus.

Authors:  Wei Wang; Bin Jin; Wei Li; Chun-Xiao Xu; Fu-Ai Cui; Bin Liu; Yun-Fei Yan; Xian-Xi Liu; Xiu-Li Wang
Journal:  Mol Biol Rep       Date:  2009-10-30       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.